Search

Your search keyword '"Pavoni, M."' showing total 234 results
Start Over Author "Pavoni, M."
234 results on '"Pavoni, M."'

3. Integrating controlled-source and ambient noise seismic measures for archaeological prospection: the Scrovegni Chapel case

Author

Barone, I, Cassiani, G, Ourabah, A, Boaga, J, Pavoni, M, and Deiana, R

Subjects
Geophysics, Geochemistry and Petrology
Abstract

SUMMARY In this paper, we present the results of an analysis of passive seismic noise recorded around the Scrovegni Chapel in Padua (Italy), using a dense 2-D network with nearly 1500 autonomous seismic nodes. Surface wave tomography using the active records allowed the imaging of several structures located at a depth of few metres, while this study focuses on the processing of about 22 hr of continuous passive records. First, the ambient noise is characterized in terms of amplitude, frequency content and azimuthal distribution, in order to ensure the applicability of the interferometric method. Second, a cross-correlation analysis is performed to retrieve virtual source gathers. Third, traveltimes are extracted from virtual source gathers using the same processing sequence applied to active gathers. Fourth, Eikonal tomography is run to retrieve isotropic phase velocity maps and azimuthal anisotropy. We compare and discuss the results obtained from the active and the passive methods, and finally propose a strategy for the integration of passive and active information. The new quasi-3-D shear wave velocity model obtained from the joint active and passive analysis is more accurate at depth, due to the addition of the passive low-frequency information.

Published
2022
Full Text
View/download PDF

4. Antibiotic Resistance and Therapy Outcome in H. pylori Eradication Failure Patients

Author

Saracino I.M., Pavoni M., Zullo A., Fiorini G., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., and Vaira D.

Subjects
h. pylori, non-naïve patients, antibiotic resistance, antibiotic susceptibility test, rescue therapies, Therapeutics. Pharmacology, RM1-950
Abstract

Helicobacter pylori (H. pylori) eradication fails in a definite amount of patients despite one or more therapeutic attempts. Curing these patients is progressively more difficult, due to development of antibiotic resistance. Current guidelines suggest testing antibiotic susceptibility in H. pylori isolates following two therapeutic attempts. Aim: to evaluate the development of antibiotic resistance, MIC values trends and therapeutic outcomes in patients who failed at least one H. pylori eradication therapy. Methods: consecutive patients, referred to perform upper gastrointestinal endoscopy (UGIE) to our Unit from January 2009 to January 2019 following at least one therapeutic attempt were considered. Bacterial resistance towards clarithromycin, metronidazole and levofloxacin was tested. Patients received either a susceptibility-guided therapy or Pylera®. Results: a total of 1223 patients were H. pylori positive, and antibiotic susceptibility was available for 1037. The rate of antibiotic resistance and MIC values significantly increased paralleling the number of previous therapeutic attempts. Eradication rates of antibiogram-tailored therapies remained stable, except for the sequential therapy if used as a third line. As a rescue treatment, the Pylera® therapy achieved cure rates comparable to those of the other culture-guided therapies. Conclusions: A significant increase in the secondary resistance towards the three tested antibiotics was observed, both as rate and MIC values, in correlation with the number of therapy failures. These findings should be considered when administering an empirical second-line therapy. Pylera® therapy eradication rates are comparable to culture-tailored therapies.

Published
2020
Full Text
View/download PDF

6. Recent Advances in the Evaluation of Serological Assays for the Diagnosis of SARS-CoV-2 Infection and COVID-19

Author

Chiereghin A., Zagari R. M., Galli S., Moroni A., Gabrielli L., Venturoli S., Bon I., Rossini G., Saracino I. M., Pavoni M., Lafratta S., Deni A., Felici S., Borghi M., Guerra L., Raumer L., Lodi V., Viale P., Attard L., Lazzarotto T., Borgatti E. C., Leone M., Mancini R., Petrisli E., Turello G., Gaibani P., Vocale C., Roncarati G., Magnani S., Fioro M. A., Fava M., Marzaduri A., Di Felice G., Caveduri F., Chiereghin A., Zagari R.M., Galli S., Moroni A., Gabrielli L., Venturoli S., Bon I., Rossini G., Saracino I.M., Pavoni M., Lafratta S., Deni A., Felici S., Borghi M., Guerra L., Raumer L., Lodi V., Viale P., Attard L., Lazzarotto T., Borgatti E.C., Leone M., Mancini R., Petrisli E., Turello G., Gaibani P., Vocale C., Roncarati G., Magnani S., Fioro M.A., Fava M., Marzaduri A., Di Felice G., and Caveduri F.

Subjects
Coronavirus disease 2019 (COVID-19), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Antibodies, Viral, COVID-19 Serological Testing, law.invention, Serology, 03 medical and health sciences, 0302 clinical medicine, ECLIA and ELISA, law, Humans, Medicine, 030212 general & internal medicine, Reference standards, SARS-CoV-2 RT-PCR, Original Research, Chemiluminescence, 0303 health sciences, biology, Plasma samples, SARS-CoV-2, 030306 microbiology, business.industry, lcsh:Public aspects of medicine, SARS-CoV-2 infection, Public Health, Environmental and Occupational Health, COVID-19, lcsh:RA1-1270, LFIA, SARS-CoV-2-specific antibodies, Immunoglobulin M, ROC Curve, Fully automated, SARS-CoV-2-specific antibodie, sensitivity and specificity, Immunoglobulin G, Immunology, biology.protein, Public Health, Antibody, CLIA, business
Abstract

Introduction: Few data on the diagnostic performance of serological tests for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are currently available. We evaluated sensitivity and specificity of five different widely used commercial serological assays for the detection of SARS-CoV-2–specific IgG, IgM, and IgA antibodies using reverse transcriptase-PCR assay in nasopharyngeal swab as reference standard test.Methods: A total of 337 plasma samples collected in the period April–June 2020 from SARS-CoV-2 RT-PCR positive (n = 207) and negative (n = 130) subjects were investigated by one point-of-care lateral flow immunochromatographic assay (LFIA IgG and IgM, Technogenetics) and four fully automated assays: two chemiluminescence immunoassays (CLIA-iFlash IgG and IgM, Shenzhen YHLO Biotech and CLIA-LIAISON® XL IgG, DiaSorin), one electrochemiluminescence immunoassay (ECLIA-Elecsys® total predominant IgG, Roche), and one enzyme-linked immunosorbent assay (ELISA IgA, Euroimmune).Results: The overall sensitivity of all IgG serological assays was >80% and the specificity was >97%. The sensitivity of IgG assays was lower within 2 weeks from the onset of symptoms ranging from 70.8 to 80%. The LFIA and CLIA-iFlash IgM showed an overall low sensitivity of 47.6 and 54.6%, while the specificity was 98.5 and 96.2%, respectively. The ELISA IgA yielded a sensitivity of 84.3% and specificity of 81.7%. However, the ELISA IgA result was indeterminate in 11.7% of cases.Conclusions: IgG serological assays seem to be a reliable tool for the retrospective diagnosis of SARS-CoV-2 infection. IgM assays seem to have a low sensitivity and IgA assay is limited by a substantial rate of indeterminate results.

Published
2021

8. Antibiotic resistance and therapy for H. pylori infection in immigrant patients managed in Italy

Author

Fiorini G, Saracino IM., Zullo A, Pavoni M., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., Vaira D., and Fiorini G, Saracino IM., Zullo A, Pavoni M., Saccomanno L., Lazzarotto T., Cavallo R., Antonelli G., Vaira D.

Subjects
resistance, therapy, Helicobacter pylori, immigrant
Abstract

Background: Helicobacter pylori (H. pylori) infection is the leading cause of both peptic ulcers and gastric tumors, including low-grade MALT-lymphoma and adenocarcinoma. Although it is decreasing in developed countries, H. pylori prevalence remains high in developing areas, mainly due to low socio-economic levels, and the potential consumption of contaminated water. Moreover, a dierent pattern of primary antibiotic resistance is expected in their H. pylori isolates, potentially aecting the ecacy of standard eradication therapies. Indeed, a previous study showed the eradication rate following triple therapy was distinctly lower in dyspeptic H. pylori infected immigrants living in Italy as compared to Italian patients. Aims: to evaluate the resistance pattern in H. pylori isolates from immigrant patients in Italy, and the success rate of first-line therapy in these patients. Materials and Methods: This retrospective study evaluated data of consecutive immigrant patients, diagnosed with H. pylori infection in a single center (Bologna, Italy) between January 2009 and January 2019. Patients underwent first-line therapy with either sequential or Pylera® (Allergan USA, Inc. Madison, NJ, USA) therapy. Results: A total of 609 immigrants were diagnosed with H. pylori infection during the study period, but 264 previously received an eradication therapy. Therefore, the study was focused on 294 out of 345 naïve patients with a successful bacterial culture with antibiogram. Latin America immigrants had the highest overall resistance rate. Levofloxacin resistance rate was significantly higher in Latin Americans and Asians as compared with Europeans. Based on resistance patterns, sequential therapy showed a clear decreasing trend in eradication rates. Conclusions: while antibiotic resistance rates are generally increasing worldwide, Pylera® seems to achieve a good performance as first-line treatment in all naïve foreigner patients, except for Africans.

Published
2020

10. OC.08.5 EFFECTIVENESS OF EMPIRICAL SECOND-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Author

Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Francis, M., additional, O”Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional

Published
2021
Full Text
View/download PDF

11. OC.08.4 ANTIBIOTIC RESISTANCE TRENDS OF ITALIAN H. PYLORI NAÏVE PATIENTS BETWEEN 2013-2020: ANALYSIS OF THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Author

Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Francis, M., additional, O”Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional

Published
2021
Full Text
View/download PDF

12. AF.24 CHARACTERISTICS OF EMPIRICAL FIRST- AND SECOND-LINE TREATMENT BETWEEN 2013-2020: ITALIAN DATA FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Author

Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Mégraud, F., additional, O’Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional

Published
2021
Full Text
View/download PDF

14. OC.08.2 EFFECTIVENESS OF EMPIRICAL FIRST-LINE H. PYLORI ERADICATION THERAPY IN ITALY: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG)

Author

Gatta, L., primary, Fiorini, G., additional, Saracino, I.M., additional, Pavoni, M., additional, Romano, M., additional, Gravina, A.G., additional, Granata, L., additional, Pellicano, R., additional, Gasbarrini, A., additional, Di Leo, A., additional, Losurdo, G., additional, Franceschi, F., additional, Nardone, G., additional, Rocco, A., additional, Dore, M.P., additional, Farinati, F., additional, Ghisa, M., additional, Puig, I., additional, Nyssen, O., additional, Mégraud, F., additional, O”Morain, C., additional, Vaira, D., additional, and Gisbert, J., additional

Published
2021
Full Text
View/download PDF

16. T02.01.18 USE OF PROBIOTICS IN THE HELICOBACTER PYLORI ERADICATION IN ITALY: DATA FROM THE “ITALIAN REGISTRY” ON H. PYLORI TREATMENT

Author

Zagari, R.M., primary, Romiti, A., additional, Saracino, I.M., additional, Ribaldone, D., additional, Panarese, A., additional, Lella, F., additional, Gigliotti, F., additional, Gasbarrini, A., additional, Del Vecchio Blanco, G., additional, Paoluzi, O.A., additional, Romano, M., additional, Annibale, B., additional, Broglia, L., additional, Catanzaro, R., additional, Marfinati Hervoso, C., additional, Luzza, F., additional, Nardone, G., additional, Grande, G., additional, Conigliaro, R., additional, Cannizzaro, R., additional, Fiorini, G., additional, Pavoni, M., additional, Vaira, B., additional, Pellicano, R., additional, Ferrara, M., additional, and Bazzoli, F., additional

Published
2020
Full Text
View/download PDF

18. Use of probiotics in the Helicobacter pylori eradication in Italy: data from the Italian Registry on Helicobacter pylori treatment

Author

Zagari, R., Romiti, A., Fiorini, G., Saracino, I., Ribaldone, D., Panarese, A., Lella, F., Gigliotti, F., Gasbarrini, A., Paoluzi, O., Del Vecchio Blanco, G., Romano, M., Annibale, B., Broglia, L., Catanzaro, R., Marfinati Hervoso, C., Luzza, F., Nardone, G., Conigliaro, R., Cannizzaro, R., Pavoni, M., Vaira, B., Pellicano, R., Ferrara, M., and Bazzoli, F.

Published
2019

29. Buchbesprechungen

Author

Pavoni, M., Staub, Robert, Woker, Staub, Robert, Wubrmann, K., Grönseth, J., Sulzer, Fritz, Braun, R., Woker, H., and Kuisel, H. F.

Published
1959
Full Text
View/download PDF

38. A factor analytic study of the Italian National Institute of Health Quality of Life – Core Evaluation Form (ISSQoL-CEF)

Author

Lauriola,M, Murri,R, Massella,M, Mirra,M, Donnini,S, Fragola,Vincenzo, Ivanovic,J, Pavoni,M, Mancini,G, Bucciardini,R, Lauriola,M, Murri,R, Massella,M, Mirra,M, Donnini,S, Fragola,Vincenzo, Ivanovic,J, Pavoni,M, Mancini,G, and Bucciardini,R

Abstract

M Lauriola1, R Murri3, M Massella4, M Mirra4, S Donnini4, V Fragola4, J Ivanovic5, M Pavoni6, G Mancini2, R Bucciardini41Department of Social and Developmental Psychology, 2Department of Infectious and Tropical Diseases, University of Rome “La Sapienza”, Rome, Italy; 3Catholic University of “Sacro Cuore”, Rome, Italy; 4Istituto Superiore di Sanità, Rome, Italy; 5National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, Italy; 6Ospedale Civile Santa Maria delle Croci, Ravenna, ItalyObjectives: The Italian National Institute of Health Quality of Life – Core Evaluation Form (ISSQoL-CEF) is a specific questionnaire measuring health-related quality of life for human immunodeficiency virus-infected people in the era of highly active antiretroviral therapy. The main goal of this study was to examine the construct validity of this questionnaire by confirmation of its hypothesized dimensional structure.Methods: Baseline quality of life data from four clinical studies were collected and a confirmatory factor analysis of the ISSQoL-CEF items was carried out. Both first-order and secondorder factor models were tested: Model 1 with nine correlated first-order factors; Model 2 with three correlated second-order factors (Physical, Mental, and Social Health); Model 3 with two correlated second-order factors (Physical and Mental/Social Health); Model 4 with only one second-order factor (General Health).Results: A total of 261 patients were surveyed. Model 1 had a good fit to the data. Model 2 had an acceptable fit to the data and it was the best of all hierarchical models. However, Model 2 fitted the data worse than Model 1.Conclusions: The findings of in this study, consistent with the results of previous study, pointed out the construct validity of the ISSQoL-CEF.Keywords: confirmatory factor analysis, HRQoL, patient-reported outcomes

Published
2010

46. Fainardi E.; Paolino E.; Ruppi P.; Bedetti A.; Govoni V.; Tola M.R.; Granieri E.; Ghinelli F.; Carre

Author

Paolino, E., Fainardi, E., Rosatti, G., Casetta, Ilaria, Govoni, Vittorio, Monetti, V. C., Tola, M. R., Granieri, Enrico Gavino Giuseppe, Carreras, M., Aiello, I., Caniatti, L., Malagù, S., D'Alessandro, R., Pavoni, M., Casmiro, M., Benassi, G., Gamberini, G., and Atobelli, A.

Subjects
Ferrara, malattie neurologiche, epidemiologia, Ferrara, Sardegna, epidemiologia, NO
Published
1991

49. Genotype-phen type correlation and prognostic assessment in 463 patients with myotonic dystrophy

Author

Gennarelli, M., primary, Novelli, G., additional, Pavoni, M., additional, Andreasi-Bassi, F., additional, Martorrell, L., additional, Cornet, M., additional, Menegazzo, E., additional, Mostacciuolo, M.L., additional, Martinez, J.M., additional, Angelini, C., additional, Pizzuti, A., additional, Baiget, M., additional, and Dallapiccola, B., additional

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results